Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
ObjectiveThe present study aimed to evaluate the predictive factors that predict outcomes of HER2-low breast cancer patients who did not achieve pathological complete response(pCR) after neoadjuvant chemotherapy (NAC).MethodsThis study included patients with HER2-low breast cancer who received NAC f...
Saved in:
| Main Authors: | Yingbo Shao, Huijuan Guan, Zhifen Luo, Yang Yu, Yaning He, Qi Chen, Chaojun Liu, Fangyuan Zhu, Hui Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1459444/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2025-03-01) -
Response and prognosis to neoadjuvant chemotherapy in women early breast cancer of HER2-low status
by: Yongtao Li, et al.
Published: (2025-06-01) -
Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy
by: Rumeysa Colak, et al.
Published: (2025-06-01) -
Higher baseline platelet and preoperative platelets to lymphocytes ratio was associated with a higher incidence of axillary node pathologic complete response after neoadjuvant chemotherapy in HER2-low breast cancer: a retrospective cohort study
by: Shuai Yang, et al.
Published: (2025-03-01) -
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
by: Sedat Yıldırım, et al.
Published: (2025-05-01)